JP2006502236A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502236A5
JP2006502236A5 JP2004568900A JP2004568900A JP2006502236A5 JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5 JP 2004568900 A JP2004568900 A JP 2004568900A JP 2004568900 A JP2004568900 A JP 2004568900A JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5
Authority
JP
Japan
Prior art keywords
tgf
pharmaceutical composition
disease state
related disease
scleroderma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004568900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003825 external-priority patent/WO2004026307A1/en
Publication of JP2006502236A publication Critical patent/JP2006502236A/ja
Publication of JP2006502236A5 publication Critical patent/JP2006502236A5/ja
Abandoned legal-status Critical Current

Links

JP2004568900A 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体 Abandoned JP2006502236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41207902P 2002-09-18 2002-09-18
US48453503P 2003-07-02 2003-07-02
PCT/IB2003/003825 WO2004026307A1 (en) 2002-09-18 2003-09-08 Triazole derivatives as transforming growth factor (tgf) inhibitors

Publications (2)

Publication Number Publication Date
JP2006502236A JP2006502236A (ja) 2006-01-19
JP2006502236A5 true JP2006502236A5 (enExample) 2006-10-05

Family

ID=32033582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004568900A Abandoned JP2006502236A (ja) 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体

Country Status (25)

Country Link
US (2) US7053095B2 (enExample)
EP (1) EP1542685A1 (enExample)
JP (1) JP2006502236A (enExample)
KR (1) KR20050057393A (enExample)
CN (1) CN1681502A (enExample)
AP (1) AP2005003260A0 (enExample)
AR (1) AR041276A1 (enExample)
AU (1) AU2003260810A1 (enExample)
BR (1) BR0314577A (enExample)
CA (1) CA2497971A1 (enExample)
CO (1) CO5540390A2 (enExample)
EA (1) EA200500376A1 (enExample)
EC (1) ECSP055681A (enExample)
HR (1) HRP20050251A2 (enExample)
IS (1) IS7713A (enExample)
MA (1) MA27442A1 (enExample)
MX (1) MXPA05002982A (enExample)
NO (1) NO20051010L (enExample)
OA (1) OA12927A (enExample)
PA (1) PA8583401A1 (enExample)
PE (1) PE20050074A1 (enExample)
PL (1) PL375974A1 (enExample)
TW (1) TW200412346A (enExample)
UY (1) UY27981A1 (enExample)
WO (1) WO2004026307A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
BR0314302A (pt) * 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
WO2004026859A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
AU2003256003A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CN101163684B (zh) 2005-02-23 2012-08-29 盐野义制药株式会社 具有酪氨酸激酶抑制作用的喹唑啉衍生物
AU2006272652B2 (en) * 2005-07-25 2011-06-16 Synta Pharmaceuticals Corp. 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
KR20080082618A (ko) * 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Alk5 조절제를 사용한 안압의 조절
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
ES2966030T3 (es) 2012-10-05 2024-04-18 Kadmon Corp Llc Anticuerpos anti-VEGFR-2/KDR humanos
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
WO2019183245A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN112867724B (zh) 2018-07-23 2024-06-04 熙源安健医药(北京)有限公司 二膦酸盐药物缀合物
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
JPS6025142A (ja) 1983-07-21 1985-02-07 Matsushita Electric Ind Co Ltd 表示装置の電極製造方法
DE3486009T2 (de) * 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
DE69821132T2 (de) * 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE60203263T2 (de) 2001-02-02 2006-02-09 Smithkline Beecham Corp. Pyrazolderivate gegen tgf überexprimierung
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
TW200417547A (en) 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds

Similar Documents

Publication Publication Date Title
JP2006502236A5 (enExample)
HUS1500021I1 (hu) 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
PL1611091T3 (pl) Podstawione pochodne kwasów fenyloalkanowych i ich zastosowanie do leczenia chorób układu oddechowego
JP2003503454A5 (enExample)
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2005507892A5 (enExample)
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
JP2006514116A5 (enExample)
JP2007510667A5 (enExample)
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
JP2008513426A5 (enExample)
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
JP2009500045A5 (enExample)
JP2009516719A5 (enExample)
JP2008513427A5 (enExample)
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
JP2008533079A5 (enExample)
CL2004001272A1 (es) Compuestos derivados de 3-(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-1,1-disustituido-urea; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento del compuesto en el tratamiento de enfermedades relacionadas co
EP1827459A4 (en) THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
JP2006505577A5 (enExample)
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12